{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-005919","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.735456+00:00","generated_at":"2026-05-17T13:49:16.872822+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"VolitionRx Q2 2025 revenue ~$0.4M; net loss down 11% YoY; expects first human licensing deal","bullets":["Q2 2025 revenue just over $0.4M; H1 2025 revenue up 15% YoY.","Net loss decreased 11% in Q2 and 24% in H1 vs prior year; operating cash burn down 30% to $10.6M in H1.","Cash & equivalents $2.3M at June 30, 2025; received $1.2M from direct offering post-quarter (director participation).","Management expects first human diagnostics out-licensing deal in Q3 2025; confidential discussions with >10 companies.","Conference call scheduled for August 15, 2025 at 8:30 a.m. ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-005919","json":"https://secwatch.observer/filing/0001477932-25-005919.json","markdown":"https://secwatch.observer/filing/0001477932-25-005919.md","text":"https://secwatch.observer/filing/0001477932-25-005919.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793225005919/0001477932-25-005919-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793225005919/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:49:16.872822+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}